Liquidia Stock Gets Stronger EPS Estimate from HC Wainwright

Liquidia Corporation (NASDAQ:LQDA) – Stock analysts at HC Wainwright boosted their FY2028 earnings estimates for Liquidia in a research report issued to clients and investors on Thursday, October 15th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $4.94 per share for the year, up from their previous estimate of $4.49. HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.05 per share. HC Wainwright also issued estimates for Liquidia’s FY2029 earnings at $5.61 EPS and FY2030 earnings at $6.36 EPS.

LQDA has been the subject of a number of other research reports. Citigroup reissued a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. Needham & Company LLC decreased their price target on Liquidia from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Jefferies Financial Group raised Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Finally, Wedbush set a $58.00 price objective on Liquidia in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $72.85.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $34.13 on Monday. The firm has a market cap of $3.05 billion, a P/E ratio of 25.07, a PEG ratio of 0.30 and a beta of 0.61. Liquidia has a twelve month low of $21.94 and a twelve month high of $93.61. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average of $58.95 and a 200 day moving average of $61.70.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of LQDA. Bank of New York Mellon Corp purchased a new stake in shares of Liquidia during the 2nd quarter valued at about $29,694,000. Bank of America Corp DE boosted its holdings in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares during the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Liquidia in the first quarter worth approximately $9,337,000. Eversept Partners LP boosted its holdings in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after buying an additional 167,949 shares during the last quarter. Finally, Seven Fleet Capital Management LP grew its position in Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock valued at $7,732,000 after buying an additional 113,609 shares during the period. 64.54% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Liquidia

In other news, insider Sanjeev Khindri sold 1,101 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $31,356.48. Following the transaction, the insider directly owned 64,846 shares of the company’s stock, valued at $1,846,814.08. This represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 9,218 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $262,528.64. Following the completion of the transaction, the insider owned 126,368 shares in the company, valued at approximately $3,598,960.64. This trade represents a 6.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 666,598 shares of company stock worth $34,796,390. 25.60% of the stock is owned by corporate insiders.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with pulmonary hypertension and other serious cardiopulmonary diseases. The company is headquartered in Research Triangle Park, North Carolina, and uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition for inhaled and injectable medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder formulation of treprostinil delivered through a proprietary inhaler.